BIA Separations and University of Zagreb in virus and viral vector purification agreement

21st February 2020
Bio-chromatography specialist BIA Separations has signed a licensing agreement with the University of Zagreb to commercialize a novel elution method that helps preserve the integrity, infectivity and potency of viruses during immunoaffinity purification. The University of Zagreb will provide BIA Separations with access to proprietary technology, while BIA Separations will market the technology to the biopharma, biotech and life science sectors on a global basis. Research teams from the two organizations will collaborate on developing follow-on technologies to support the purification of viruses and viral vectors for research and clinical use.
One of the key disadvantages of the immunoaffinity chromatography is partial degradation of viral particles as a result of low pH conditions required for the elution. The technology overcomes this by using a concentrated solution of specifically selected amino acids and their salts, maintaining a neutral pH (6.0 – 8.0), resulting in the highly effective elution from an immunoaffinity chromatographic support of intact and functional viruses for gene therapy application.
BIA Separations will commercialize the technology through sales of the company’s core separations products and services, or as individual licence agreements.
Aleš Štrancar, CEO of BIA Separations, commented: “BIA Separations’ monolithic column technology is now well established and following this success we are focused on providing customers with a ‘one-stop-shop’ for the manufacture of gene therapy vectors, vaccines, exosomes, DNA/RNA and any novel complex biopharma product. In order to achieve fully integrated upstream and downstream processing with robust in-process control we are collaborating with other leaders in the industry to access the latest technologies and products. This agreement with the University Zagreb is one of a number currently in the pipeline and supports our ultimate goal.”